SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (2015)3/17/1999 10:43:00 AM
From: M. Ramle  Read Replies (2) | Respond to of 10280
 
Don:

Thanks for the info. What puzzles me here is the trading harmony between LLY & SEPR of late. I would think that if LLY was not relying on SEPR for it's new "super" Prozac, then they would trade in opposite directions.

Lately, SEPR has been acting weak on LLY weakness and vice-versa, and to me that shows some kind of a link between the two concerning the FTC Investigation.

Mazen



To: Don Miller who wrote (2015)3/17/1999 10:52:00 AM
From: j_fir2  Respond to of 10280
 
They want to make quite sure LLY is seen as the dominant player, IMHO.

SEPR's been moving so well since Southwell had his TV appearance. We're waiting for Xonepex's approval. There aren't enough shares for major institutional investors to get too involved...plus they MIGHT wait until there is more, um, certainty... $140/share on -$4/share earnings...An FTC challenge in the wings. Hmm, I've alsmost talked myself into taking some profits. Naaaa...I don't think so.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News